Celldex Readies for Key Phase 2 Barzolvolimab Showcases
Celldex Gears Up for Major Presentations at EAACI Congress 2025
HAMPTON, N.J. — Celldex (NASDAQ: CLDX) is excited to announce the upcoming presentations of its Phase 2 study data on barzolvolimab, focusing on chronic spontaneous urticaria (CSU) at the acclaimed EAACI Congress 2025 occurring in Glasgow. This Congress is a centerpiece for allergy and immunology advancements, making it an ideal venue for showcasing significant research.
Presentation Details for the EAACI Congress
The company has shared that detailed findings from the study will be made available on the event's official website shortly after the event kicks off. Specifically, the abstracts are set to be released on June 12, allowing attendees a chance to delve into key insights before the actual presentations.
Celldex will be hosting an informative webcast aimed at discussing these findings comprehensively. Scheduled for June 12 at 6:00 pm ET, this session is expected to be a great opportunity for investors and the medical community to hear directly from the experts involved. Along with company representatives, Martin Metz, MD, an esteemed professor from the Department of Dermatology and Allergy, will lead discussions following the data presentation.
How to Access the Webcast
Participants interested in this webcast can find the registration details in the Events section located on Celldex's Investor Relations page. For those opting to join via phone, a registration link will provide the necessary dial-in numbers and a unique PIN for seamless access.
Substantial Findings Anticipated
One of the pivotal sessions will take place on June 13 at 9:12 am BST where an oral presentation titled “Sustained Disease Control Following Withdrawal of Barzolvolimab in Patients with Chronic Spontaneous Urticaria” will be featured, delivered by Dr. Ana Maria Giménez-Arnau, MD, PhD. This presentation is expected to highlight the long-term efficacy of barzolvolimab in managing symptoms of CSU.
Follow-up Insights on Angioedema
Moreover, on June 14 at 3:48 pm BST, another important presentation will focus on angioedema associated with CSU. The oral presentation will detail findings on how barzolvolimab administration over 52 weeks leads to consistent improvements in angioedema symptoms. Dr. Metz will also present this significant research.
Celldex's Mission in Immunology
Celldex continues to be at the forefront of immunology, passionately striving to develop pioneering therapies aimed at addressing allergic, inflammatory, and autoimmune disorders. The company’s relentless focus on innovative, antibody-based treatments aims to engage the human immune system effectively.
The dedication and thorough research underpinning their treatments not only aim to relieve symptoms but also to elevate the quality of life for patients enduring these challenging conditions. This commitment is apparent as Celldex tailors each aspect of their research towards enhancing patient outcomes.
Stay Updated with Celldex
For more ongoing updates and detailed information regarding research and innovatory projects, interested parties are encouraged to visit the company's website.
Company Contacts
For additional inquiries, reach out to:
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com
Frequently Asked Questions
What is the focus of Celldex's upcoming presentations?
The presentations will center around the Phase 2 study data of barzolvolimab in chronic spontaneous urticaria, showcasing both efficacy and tolerability.
When will the presentations take place?
The presentations are scheduled for June 13 and June 14, 2025, during the EAACI Congress in Glasgow.
Who will be presenting the findings on barzolvolimab?
Dr. Ana Maria Giménez-Arnau and Dr. Martin Metz will be the lead presenters, sharing insights on the treatment’s efficacy and impacts.
How can one participate in the webcast?
Interested individuals can register through the Events section on Celldex's Investor Relations page to access the webcast.
What is Celldex's mission in immunology?
Celldex is focused on pioneering therapies that engage the immune system to improve lives impacted by allergic, inflammatory, and autoimmune disorders.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.